Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Non-Current Debt: 2020-2021

Historic Non-Current Debt for Insight Molecular Diagnostics (IMDX) over the last 2 years, with Sep 2021 value amounting to $178,000.

  • Insight Molecular Diagnostics' Non-Current Debt fell 91.38% to $178,000 in Q3 2021 from the same period last year, while for Sep 2021 it was $178,000, marking a year-over-year decrease of 91.38%. This contributed to the annual value of $1.5 million for FY2020, which is N/A change from last year.
  • As of Q3 2021, Insight Molecular Diagnostics' Non-Current Debt stood at $178,000, which was down 67.10% from $541,000 recorded in Q2 2021.
  • Insight Molecular Diagnostics' Non-Current Debt's 5-year high stood at $2.6 million during Q2 2020, with a 5-year trough of $178,000 in Q3 2021.
  • Over the past 2 years, Insight Molecular Diagnostics' median Non-Current Debt value was $1.5 million (recorded in 2020), while the average stood at $1.3 million.
  • Data for Insight Molecular Diagnostics' Non-Current Debt shows a maximum YoY slumped of 91.38% (in 2021) over the last 5 years.
  • Over the past 2 years, Insight Molecular Diagnostics' Non-Current Debt (Quarterly) stood at $1.5 million in 2020, then tumbled by 91.38% to $178,000 in 2021.
  • Its Non-Current Debt stands at $178,000 for Q3 2021, versus $541,000 for Q2 2021 and $951,000 for Q1 2021.